Aflac Incorporated (NYSE:AFL) Shares Sold by Orrstown Financial Services Inc.

Orrstown Financial Services Inc. trimmed its stake in shares of Aflac Incorporated (NYSE:AFL) by 16.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,000 shares of the financial services provider’s stock after selling 397 shares during the quarter. Orrstown Financial Services Inc.’s holdings in Aflac were worth $222,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Whipplewood Advisors LLC acquired a new position in shares of Aflac during the fourth quarter worth about $26,000. BankPlus Trust Department acquired a new position in Aflac during the 4th quarter worth approximately $34,000. Curio Wealth LLC acquired a new position in Aflac during the 4th quarter worth approximately $36,000. Capital A Wealth Management LLC acquired a new position in Aflac during the 4th quarter worth approximately $38,000. Finally, OFI Invest Asset Management acquired a new position in Aflac during the 4th quarter worth approximately $38,000. 67.44% of the stock is owned by institutional investors and hedge funds.

Aflac Price Performance

Shares of NYSE AFL opened at $103.71 on Monday. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.10 and a quick ratio of 0.08. The stock has a fifty day moving average price of $105.39 and a 200 day moving average price of $105.87. Aflac Incorporated has a 1-year low of $86.46 and a 1-year high of $115.50. The company has a market cap of $56.07 billion, a PE ratio of 10.80, a P/E/G ratio of 3.24 and a beta of 0.82.

Aflac (NYSE:AFL) last released its earnings results on Wednesday, April 30th. The financial services provider reported $1.66 EPS for the quarter, missing the consensus estimate of $1.67 by ($0.01). Aflac had a return on equity of 16.20% and a net margin of 28.76%. The firm had revenue of $3.40 billion during the quarter, compared to analyst estimates of $4.53 billion. During the same quarter last year, the business posted $1.66 EPS. The firm’s revenue was down 37.5% on a year-over-year basis. Sell-side analysts forecast that Aflac Incorporated will post 6.88 EPS for the current year.

Aflac Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Wednesday, May 21st were given a $0.58 dividend. The ex-dividend date was Wednesday, May 21st. This represents a $2.32 dividend on an annualized basis and a yield of 2.24%. Aflac’s payout ratio is currently 36.25%.

Insider Activity at Aflac

In other Aflac news, Director Arthur Reginald Collins sold 2,750 shares of the firm’s stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $105.70, for a total value of $290,675.00. Following the completion of the sale, the director now owns 6,728 shares of the company’s stock, valued at approximately $711,149.60. This trade represents a 29.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Joseph L. Moskowitz sold 1,000 shares of the firm’s stock in a transaction on Thursday, May 8th. The shares were sold at an average price of $106.79, for a total value of $106,790.00. Following the completion of the sale, the director now directly owns 26,096 shares of the company’s stock, valued at approximately $2,786,791.84. This trade represents a 3.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,750 shares of company stock worth $4,304,295 over the last 90 days. Company insiders own 0.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on AFL. Wall Street Zen downgraded shares of Aflac from a “hold” rating to a “sell” rating in a research note on Monday, May 5th. Piper Sandler upped their price objective on Aflac from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 2nd. Keefe, Bruyette & Woods upped their target price on shares of Aflac from $104.00 to $106.00 and gave the company a “market perform” rating in a report on Wednesday, May 7th. UBS Group upped their target price on shares of Aflac from $109.00 to $114.00 and gave the company a “neutral” rating in a report on Wednesday, April 2nd. Finally, Barclays upped their price objective on shares of Aflac from $95.00 to $96.00 and gave the company an “underweight” rating in a research note on Thursday, May 1st. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $104.93.

Aflac Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.